ADRB1

ADRB1 (β1-adrenergic receptor) is a Gs-coupled GPCR that transduces catecholamine signals to regulate cardiac contractility, heart rate, and renin release, with the common Arg389 polymorphism conferring enhanced receptor-effector coupling compared to Gly389 (PMID:23114278, PMID:26313487). Receptor desensitization is mediated by GRK2, which directly binds ADRB1 to drive its internalization and downstream hypertrophic/fibrotic gene programs in cardiomyocytes; disruption of the GRK2–ADRB1 interaction blocks these pathological responses (PMID:33372534). ADRB1 expression is post-transcriptionally regulated by miR-19a targeting its 3ʹUTR and by FTO-dependent m6A demethylation of ADRB1 mRNA, the latter linking receptor abundance to adipocyte differentiation (PMID:25785039, PMID:35904284). Beyond the cardiovascular system, ADRB1 is expressed on CD4+ T cells in the tumor microenvironment where its signaling promotes T cell exhaustion, a phenotype reversible by β-blockade (PMID:40406147, PMID:41491200).

1. 2013 Medium

   Until pharmacogenomic testing in vivo, it was unclear whether the common Arg389Gly polymorphism produced measurable differences in receptor coupling in humans; genotype-stratified esmolol challenge showed that Arg389 homozygotes exhibit significantly greater heart rate inhibition, establishing this variant as a gain-of-coupling allele in vivo.

   Evidence Genotype-stratified pharmacodynamic study with intravenous esmolol during exercise in healthy volunteers

   PMID:23114278

   Open questions at the time

   • Mechanism of enhanced coupling at the structural level not resolved
   • Single-center study; effect sizes in heart failure patients unknown
   • No direct measurement of Gs activation or cAMP in these subjects
2. 2015 Medium

   Extending the Arg389 coupling observation, dobutamine infusion demonstrated ~4.7-fold greater heart rate and ~3.9-fold greater renin responses in Arg389 homozygotes versus Gly389 homozygotes, confirming enhanced agonist coupling and showing the polymorphism also affects the renin-angiotensin axis.

   Evidence Genotype-stratified dobutamine infusion with hemodynamic and plasma renin measurements in healthy volunteers

   PMID:26313487

   Open questions at the time

   • Whether renin response is a direct β1AR-kidney axis or secondary to hemodynamic changes not distinguished
   • Heterozygote phenotype incompletely characterized
3. 2015 Medium

   The mechanism controlling ADRB1 mRNA levels was unknown; miR-19a was shown to directly bind the ADRB1 3ʹUTR and suppress protein expression, establishing a post-transcriptional regulatory axis.

   Evidence Dual-luciferase 3ʹUTR reporter assay and AGO2 knockdown with western blot confirmation

   PMID:25785039

   Open questions at the time

   • Physiological contexts in which miR-19a regulates ADRB1 in vivo not defined
   • Single lab; awaits independent replication
   • Other miRNAs targeting ADRB1 not systematically assessed
4. 2020 High

   The molecular basis by which β1AR stimulation leads to pathological cardiac remodeling was clarified: GRK2 directly binds ADRB1 to drive receptor internalization and upregulation of hypertrophic/fibrotic genes, and disruption of this interaction (genetically or with paroxetine) prevents these outcomes.

   Evidence Co-immunoprecipitation of GRK2–ADRB1, GRK2 genetic knockdown in cardiomyocytes, and in vivo validation in spontaneously hypertensive rats

   PMID:33372534

   Open questions at the time

   • Specific GRK2 phosphorylation sites on ADRB1 not mapped
   • Whether paroxetine effect is entirely through GRK2–ADRB1 disruption versus off-target SSRI activity not fully excluded
   • Downstream signaling cascade from internalized receptor to hypertrophic gene induction incompletely defined
5. 2022 Medium

   An epitranscriptomic layer of ADRB1 regulation was revealed: FTO demethylates m6A on ADRB1 mRNA to increase its expression, and this axis controls adipocyte differentiation, linking β1AR levels to metabolic cell fate decisions.

   Evidence FTO and ADRB1 siRNA knockdown, MeRIP-qPCR for m6A quantification, adipogenesis assays in porcine preadipocytes

   PMID:35904284

   Open questions at the time

   • Specific m6A sites on ADRB1 mRNA not mapped
   • Whether m6A affects mRNA stability versus translation not distinguished
   • Relevance to human adipocyte biology not tested
6. 2023 Medium

   ADRB1 function was extended to neuronal circuits: ADRB1 on CaMKII+ neurons in the medial prefrontal cortex mediates heightened methamphetamine sensitivity in offspring of drug-exposed fathers, with viral knockdown and pharmacological blockade both suppressing neuronal activation and drug-seeking behavior.

   Evidence Viral ADRB1 knockdown on CaMKII+ mPFC neurons, betaxolol pharmacological blockade, conditioned place preference assay, in vivo neuronal activity recording in mice

   PMID:37857642

   Open questions at the time

   • Downstream signaling pathway in mPFC neurons (cAMP/PKA vs other) not delineated
   • Mechanism of transgenerational epigenetic upregulation of ADRB1 unknown
   • Whether finding extends to other drugs of abuse not tested
7. 2025 Medium

   ADRB1 was identified as functionally relevant on immune cells: ADRB1+ CD4+ T cells in the tumor microenvironment display elevated exhaustion markers, and pharmacological β-blockade reverses this exhaustion, restoring cytotoxic effector function against colorectal cancer in vitro and in vivo.

   Evidence Single-cell RNA-seq, immunofluorescence colocalization, FACS exhaustion marker analysis, propranolol-loaded nanoparticle treatment in CT26 models and patient-derived organoids

   PMID:40406147 PMID:41491200

   Open questions at the time

   • Intracellular signaling cascade linking ADRB1 to exhaustion transcriptional program not defined
   • Propranolol is non-selective (β1/β2); contribution of β2AR blockade not excluded
   • Clinical relevance of ADRB1 blockade in human cancer immunotherapy untested

• Key unresolved questions include the structural basis for Arg389-enhanced coupling, the identity of GRK2 phosphorylation sites on ADRB1 that trigger internalization, and the signaling pathway by which ADRB1 drives T cell exhaustion in the tumor microenvironment.
• No high-resolution structure of active human ADRB1 with Gs bound at Arg389 position
• GRK2 phosphorylation sites on ADRB1 not mapped
• ADRB1-driven T cell exhaustion signaling intermediates unknown